InflaRx NV (InflaRx NV) Interest Expense : $-0.04 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. InflaRx NV's interest expense for the three months ended in Mar. 2024 was $ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.04 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. InflaRx NV's Operating Income for the three months ended in Mar. 2024 was $ -13.58 Mil. InflaRx NV's Interest Expense for the three months ended in Mar. 2024 was $ -0.01 Mil. InflaRx NV did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

InflaRx NV Interest Expense Historical Data

The historical data trend for InflaRx NV's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Interest Expense Chart

InflaRx NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.02

-0.03

-0.05

-0.04

InflaRx NV Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.01	-0.01	-0.01	-0.02	-0.01

InflaRx NV Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04 Mil.

InflaRx NV (NAS:IFRX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

InflaRx NV's Interest Expense for the three months ended in Mar. 2024 was $-0.01 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-13.58 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.79 Mil.

InflaRx NV's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

InflaRx NV did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

InflaRx NV (InflaRx NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

IF0:Germany IF0:Germany

Address

Winzerlaer Strasse 2, Jena, DEU, 07745

Website

https://www.inflarx.de

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.